Evidence map›Paper›PMID 25560865›Full record

ReviewChest2015

Intermittent hypoxemia and OSA: implications for comorbidities.

Naresh A Dewan, F Javier Nieto, Virend K Somers

Open access · bronzeAbstract readReview
In one paragraph

Review in Chest, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 329 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 12 pooled it
25.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

329 citing papers in PubMed, 12 syntheses or guidelines pooled it, 614 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Sleep Disorders in Cancer-A Systematic Review.International journal of environmental research and public health · 2021
    Pooled it
  12. Pooled it
  13. Trial
  14. Polysomnographic phenotypes: predictors of treatment response in Obstructive Sleep Apnea with Mandibular Advancement devices.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Trial
  15. Trial
  16. Trial
  17. Effect of mandibular advancement device on plasticity in corticomotor control of tongue and jaw muscles.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021
    Trial
  18. Nocturnal Hypoxemia Burden Correlates With Vestibular Dysfunction in Obstructive Sleep Apnea.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026
    Article
  19. Article
  20. Article

269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Naresh A DewanDivision of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN.. Electronic address: ndewan@creighton.edu.
F Javier NietoDepartment of Medicine, Creighton University and Pulmonary Section, Omaha VA Medical Center, US Department of Veterans Affairs, Omaha, NE; Population Health Sciences, School of Medicine and Public Health, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN; Population Health Sciences, School of Medicine and Public Health, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN.
Virend K SomersDivision of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN.; University of Wisconsin-Madison, Board of Regents of the University of Wisconsin System, Madison, WI; and Sleep and Cardiovascular Clinical Research Unit, College of Medicine, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN; Sleep and Cardiovascular Clinical Research Unit, College of Medicine, Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN.
Mayo Clinic · US

Funding

EPIDEMIOLOGY OF SLEEP-DISORDERED BREATHING IN ADULTSR01HL062252 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI PEPPARD, PAUL E · 1999 to 2013
$14.1M
Disease Mechanisms in Sleep ApneaR01HL065176 · NHLBI · MAYO CLINIC ROCHESTER · PI SOMERS, VIREND K · 1999 to 2021
$5.8M
NHLBI NIH HHS HL-65176NHLBI NIH HHS R01 HL062252NHLBI NIH HHS R01HL062252-11NHLBI NIH HHS R01 HL065176
6 · The paper itself

Abstract

OSA is a common chronic disorder that is associated with significant morbidity and mortality including cardiovascular, metabolic, and neurocognitive disease and increased cancer-related deaths. OSA is characterized by recurrent episodes of apneas and hypopneas associated with repetitive episodes of intermittent hypoxemia, intrathoracic pressure changes, and arousals. Intermittent hypoxemia (IH) is now being recognized as a potential major factor contributing to the pathogenesis of OSA-related comorbidities. OSA-related high-frequency IH is characterized by cycles of hypoxemia with reoxygenation that is distinctly different than sustained low-frequency hypoxia and contributes to ischemia-reperfusion injury. Data from both animal and human studies support mechanistic links between IH and its adverse impact at the tissue level. IH promotes oxidative stress by increased production of reactive oxygen species and angiogenesis, increased sympathetic activation with BP elevation, and systemic and vascular inflammation with endothelial dysfunction that contributes to diverse multiorgan chronic morbidity and mortality affecting cardiovascular disease, metabolic dysfunction, cognitive decline, and progression of cancer. Data from observational studies in large population groups also support the role for hypoxia in the pathogenesis of OSA comorbidity. Treatment with CPAP to reverse OSA-related symptoms and comorbidities has been shown to provide variable benefit in some but not all patient groups. Early treatment with CPAP makes intuitive sense to promote maximal functional recovery and minimize residual injury. More studies are needed to determine the interacting effects of IH and obesity, differential effects of both short-term and long-term hypoxemia, and the effect of CPAP treatment.

Indexed as

Cardiovascular DiseasesChronic DiseaseComorbidityGlobal HealthHumansHypoxiaRisk FactorsSleep Apnea, Obstructive

Identifiers

PMID25560865
PMCPMC4285080
OpenAlexW2067956022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.